Interactions in man of delta-9-tetrahydrocannabinol. II. Cannabinol and cannabidiol.
Clinical pharmacology and therapeutics July 1975 DOI: 10.1002/cpt197518180 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Experimental study Peer reviewed |
|---|---|
| Population | Human volunteers |
| Interventions | delta-9-tetrahydrocannabinol (THC) cannabinol (CBN) cannabidiol (CBD) |
| Dose | 20 mg THC; 40 mg CBN; 40 mg CBD |
| Topics | Cannabis CBD |
| Key findings | CBN at 40 mg did not detectably alter the quality, intensity, or duration of THC's effects, while CBD at 40 mg tended to delay THC's onset, prolong its effects, and make them somewhat more intense. The authors judge this interaction slight and argue it provides no reason to abandon dosing marijuana for clinical studies solely on THC content. |
Abstract
Oral doses of delta-9-tetrahydrocannabinol (THC) 20 mg, combined with placebo or with 40 mg dses of cannabinol (CBN) and cannabidiol (CBD), were given to volunteers. The combination of THC with CBN produced no detectable changes in the quality, intensity, or duration of the effects of THC alone. The THC-CBD combination tended to delay onset and prolong effects of THC, while making them somewhat more intense. Even this interactive effect was slight, providing no reason to abandon the current practice of basing doses of marihuana for clinical studies solely on THC content.